ReviewFrontiers in immunology2026
Global trends and knowledge evolution of tertiary lymphoid structures in cancer immunotherapy: a bibliometric and visualization analysis.
Review in Frontiers in immunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tertiary lymphoid structures (TLSs) are ectopic immune aggregates that arise in non-lymphoid tissues during chronic inflammation, including cancer. Their reported associations with antitumor immunity and immune-checkpoint blockade have prompted rapid growth of the field. We therefore mapped the literature on TLSs in cancer immunotherapy over the prespecified period from January 1, 2000 through March 31, 2026. Methods: The primary bibliometric corpus comprised 1,373 English-language articles and reviews from the Web of Science Core Collection (WoSCC). PubMed and Scopus were searched independently for descriptive comparison and were not merged with the WoSCC corpus. Analyses used bibliometrix, VOSviewer, CiteSpace, SCImago Graphica, and Microsoft Excel. Results: Publication output rose markedly after 2019 and reached 315 publications in 2025. China, the United States, and France were the leading corresponding-author countries/regions, while INSERM, Sun Yat-sen University, and Fudan University led the distinct-document institutional count. Major mapped themes included B cells, immune-checkpoint blockade, spatial pathology, prognostic modeling, the tumor microenvironment, lymphatic vessels, and high endothelial venules. The independently retrieved PubMed and Scopus datasets showed broadly similar aggregate temporal and title/abstract term profiles. Conclusion: The analysis describes the growth, collaboration structure, and thematic development of TLS research in cancer immunotherapy. These bibliometric patterns indicate research attention; they do not establish biological mechanisms, biomarker performance, therapeutic efficacy, or clinical utility.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.